Sign in

CIK 0000946644

  • Non-accelerated filer
  • Smaller reporting company

AIM ImmunoTech Inc.

Sign in to watch
Ticker
AIM
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
520845822
Phone
+1 352-448-7797
Business address
2117 SW HIGHWAY 484, OCALA, FL, 32801
Former names
AIM ImmunoTech Inc., HEMISPHERX BIOPHARMA INC
  1. 4 Open-market buy CEO & President bought 5,000 shares at $0.30 ($1,515)
  2. 4 Open-market buy CEO & President bought 20,000 shares at $0.31 ($6,160)
  3. 4 Grant or award CEO & President acquired 312,500 shares (grant or award)
  4. 4 Grant or award COO, Secretary, Gen. Counsel acquired 188,679 shares (grant or award)
  5. 4 Grant or award CEO & President acquired 377,358 shares (grant or award)
  6. 4 Open-market buy CEO & President bought 61,729 shares at $0.41 ($25,000)
  7. 4 Open-market buy COO, Secretary, Gen. Counsel bought 30,865 shares at $0.41 ($12,500)
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Open-market buy Director bought 38,462 shares at $0.39 ($15,000)
  11. 4 Open-market buy Director bought 90,910 shares at $0.33 ($30,000)
  12. 4 Open-market buy COO, Secretary, Gen. Counsel bought 37,879 shares at $0.33 ($12,500)
  13. 4 Open-market buy CEO & President bought 75,758 shares at $0.33 ($25,000)
  14. 4 Open-market buy CEO & President bought 33,861 shares at $0.44 ($15,000)
  15. 4 Open-market buy CEO & President bought 22,676 shares at $0.44 ($10,000)
  16. 4 Open-market buy CEO & President bought 8,222 shares at $0.67 ($5,501)
  17. 4 Open-market buy CEO & President bought 14,993 shares at $0.67 ($10,000)
  18. 4 Open-market buy CEO & President bought 16,950 shares at $0.59 ($10,001)
  19. 3 Insider Initial Statement of Ownership
  20. 4 Other disposition Director disposed of 68,208 shares (other)

Page 4 of 31 · 614 filings